Efficacy of intravitreal injection of ranibizumab combined with laser photocoagulation in the treatment of retinopathy of prematurity

Abstract

Objective To evaluate the clinical efficacy of intravitreal injection of ranibizumab combined with laser photocoagulation on the treatment of retinopathy of prematurity. Methods The data of 60 eyes of 30 cases with retinopathy of prematurity from Oct.2014 to Dec.2017 were analyzed retrospectively. All cases were treated with intravitreal injection of ranibizumab. Laser photocoagulation was treated for complications and neovascularization on the ridge. The clinical efficacy and complications were observed. Results Followed up for 6 weeks after intravitreal injection of ranibizumab, the lesions completely disappeared in 38 eyes (63.3%) with neovascular and hemorrhagic absorption, and vascular development to serrate or scar lesions. Twenty-two eyes(36.7%) recurred, included 4 eyes of threshold stage, 4 eyes of pre-threshold, and 14 eyes of aggressive posterior. The lesions of 11 cases completely disappeared after laser photocoagulation. The condition was stable and no complication occurred after treatment. No treatment related adverse reactions was found in 30 cases. Conclusion The intravitreal injection of ranibizumab combined with laser photocoagulation for retinopathy of prematurity is effective. Key words: Retinopathy, prematurity; Ranibizumab, intravitreal injection; Photocoagulation, laser